Toggle navigation
Home
Feed
Channels
Profile
Home
Feed
Channels
Profile
Medspoke's Talks
Medspoke
Medspoke
Urology (the "Gold Journal")
Published October 15, 2026
A Contemporary Analysis of Positive Surgical Margin Length and Oncologic Outcomes After Radical P...
October 16, 2026
Medspoke
Medspoke
Urologic Oncology
Published September 22, 2026
00:00
--:--
Perioperative enfortumab vedotin-pembrolizumab, gemcitabine-cisplatin-durvalumab, and dose-dense ...
October 16, 2026
Share
Perioperative enfortumab vedotin-pembrolizumab, gemcitabine-cisplatin-durvalumab, and dose-dense MVAC in cisplatin-eligible muscle-invasive bladder cancer: A benefit-risk Bayesian network meta-analysis.
https://www.medspoke.co/channel_journal?id=689&tap_id=15740
Copy Link
Email
X
Bluesky
WhatsApp
LinkedIn
Facebook
Reddit
Medspoke
Medspoke
Urologic Oncology
Published October 16, 2026
Prospectively collected functional vs. self-reported frailty measures and postoperative outcomes ...
October 16, 2026
Why are you reporting this TALK?
